Innovative €250,000 Parenteral Nutrition Research Grant Awarded by Fresenius Kabi

BAD HOMBURG, Germany, Nov. 25, 2021 /PRNewswire/ -- Fresenius Kabi was delighted to announce the winner of their innovative JUMPstart education program and research grant on September 10, 2021. JUMPstart is an initiative that aims to nurture research in the field of parenteral nutrition through the mentoring, education and networking of clinicians and researchers. The grant is awarded to help to advance novel, community-led research in parenteral nutrition, to make a difference for critically ill patients.

This year's winner is Professor Stefan Schaller M.D. of Charité – Universitätsmedizin Berlin, Germany, for his proposal entitled "Improved muscle metabolism by combination of muscle activation and protein substitution." This cutting-edge study aims to explore the effect of protein substitution before and after early, goal-directed mobilization in the acute phase of critical illness. The announcement was made at the European Society for Clinical Nutrition and Metabolism (ESPEN) Congress.

During the virtual awards ceremony, Professor Schaller said: "After working on this research proposal for a long time, me and my research team are thrilled to be able to now conduct the study, and I am very thankful to the generous grant from Fresenius Kabi. I am very optimistic that this trial will have an impact on nutrition therapy in critical care."

Professor Schaller took part in the program alongside 18 other participants from around the world, including representation from Africa, Asia, Australia, Europe, New Zealand, and North and South America. After four training sessions, participants presented their research proposals to an independent international scientific committee, which consisted of five field-leading experts: Professor Mette Berger, Switzerland; Professor Olav Rooyackers, Sweden; Professor Tim Friede, Germany; Professor Robert Martindale, USA; and Professor Ho-Seong Han, South Korea. The committee was impressed by the high-quality level of all proposals, and this made picking a winner extremely challenging.

Dr. Jos Simons, Executive Vice President at Fresenius Kabi, commented: "We are absolutely delighted to be able to award this research grant to Professor Schaller. Both the scientific committee and Fresenius Kabi were astounded by his proposal and the positive impact it will have on clinical practice. We are very excited for Professor Schaller to start this clinical study."

This is the second JUMPstart research grant worth €250,000. The first program of 19 participants completed in 2019, with the grant awarded to dietician Lizl Veldsman, Tygerberg Academic Hospital in Cape Town, South Africa.

With the JUMPstart education program and research grant, Fresenius Kabi supports the next generation of clinical experts who will contribute to advancement in nutrition therapy in critically ill patients.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.

With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

Fresenius Kabi employs around 40,500 people worldwide. In 2020, the company reported sales of around €7.0 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

For more information, please visit www.fresenius-kabi.com

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release.

Management Board: Michael Sen (Chairman), Marc Crouton, John Ducker, Dr. Oskar Haszonits, Dr. Christian Hauer, Dr. Michael Schönhofen, Gerrit Steen

Chairman of the Supervisory Board: Stephan Sturm

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg - HRB 11654

Emese Kamp
PINK CARROTS Communications GmbH 
E-mail: emese.kamp@pinkcarrots.com  
Phone: +49 69 4272614-141

Photo - https://mma.prnewswire.com/media/1693173/Fresenius_Kabi.jpg
Logo - https://mma.prnewswire.com/media/1655430/Fresenius_Kabi_Logo.jpg

SOURCE Fresenius Kabi